- Home
- MNTK vs PHAT Comparison
MNTK vs PHAT Comparison
Compare MNTK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- PHAT
- Stock Information
- Founded
- MNTK 1980
- PHAT 2018
- Country
- MNTK United States
- PHAT United States
- Employees
- MNTK N/A
- PHAT N/A
- Industry
- MNTK Natural Gas Distribution
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- MNTK Utilities
- PHAT Health Care
- Exchange
- MNTK Nasdaq
- PHAT Nasdaq
- Market Cap
- MNTK 269.2M
- PHAT 289.0M
- IPO Year
- MNTK 2021
- PHAT 2019
- Fundamental
- Price
- MNTK $2.18
- PHAT $10.42
- Analyst Decision
- MNTK Hold
- PHAT Strong Buy
- Analyst Count
- MNTK 3
- PHAT 5
- Target Price
- MNTK $3.33
- PHAT $16.40
- AVG Volume (30 Days)
- MNTK 253.7K
- PHAT 4.7M
- Earning Date
- MNTK 08-07-2025
- PHAT 08-07-2025
- Dividend Yield
- MNTK N/A
- PHAT N/A
- EPS Growth
- MNTK N/A
- PHAT N/A
- EPS
- MNTK 0.05
- PHAT N/A
- Revenue
- MNTK $179,552,000.00
- PHAT $81,859,000.00
- Revenue This Year
- MNTK $3.00
- PHAT $195.45
- Revenue Next Year
- MNTK $13.24
- PHAT $106.76
- P/E Ratio
- MNTK $41.47
- PHAT N/A
- Revenue Growth
- MNTK N/A
- PHAT 3055.70
- 52 Week Low
- MNTK $1.68
- PHAT $2.21
- 52 Week High
- MNTK $6.22
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- MNTK 49.49
- PHAT 78.59
- Support Level
- MNTK $2.03
- PHAT $4.47
- Resistance Level
- MNTK $2.46
- PHAT $11.28
- Average True Range (ATR)
- MNTK 0.17
- PHAT 1.45
- MACD
- MNTK 0.02
- PHAT 0.38
- Stochastic Oscillator
- MNTK 55.77
- PHAT 76.46
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.